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Abstract Peptides eluted from the MHC class I Kd molecule 
are generally nonamers that display a strong preference for Tyr 
iu position 2 and Ile or Leu in position 9. We investigated the 
binding ability of several synthetic peptides which did not fit this 
consensus motif. In our peptides, Ty2 was substituted by other 
amino acids, i.e. Leu, Ile or Met. These peptides were variants of 
the 252260 Kd-restricted peptide SYIPSAEKI derived from the 
Pfasmodium berghi circumsporozoite protein. They bound to 
purified Kd molecules in vitro with intermediate affinity. One of 
them was tested for in vivo stimulation of T cells and induced a 
cytotoxic response. These results demonstrate the importance of 
binding motif refinement to discover new binding characteristics 
and new ligands such as low-affinity peptides. 
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1. Introduction 
Major histocompatibility complex (MHC) class I molecules 
bind short peptides derived mainly from endogenously synthe- 
sized proteins [l]. Peptide binding to the class I molecule 
occurs in the endoplasmic reticulum (ER) and is followed 
by the egress of MHC/peptide complex to the cell surface. 
Allele specific cytotoxic T lymphocytes (CTLs) can recognize 
complexes expressing virus- or tumour-derived peptides. 
Crystallographic studies of the MHC molecules in complex 
with peptides [2,3], chemical analyses of mixtures of naturally 
occurring peptides bound to MHC alleles [4] and binding tests 
performed either with individual synthetic peptides [5,6] or 
with peptide libraries [7] revealed biochemical details of 
MHC-peptide interactions. These studies identified allele-spe- 
cific motifs containing critical or ‘anchor’ residues at defined 
positions within the sequences of peptides that bind to each 
particular allele. Peptides bound to class I molecules are S-10 
residues long. In the case of the murine MHC class I molecule 
Kd, the motif consists of a 9-mer sequence with Tyr or Phe in 
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clonal antibody; MALDI, matrix-assisted laser desorption and 
ionization; MHC, major histocompatibility complex; PBS, phos- 
phate-buffered saline; TAP, transporter associated with antigen 
processing 
position 2 counting from the N-terminus (Tyr’ or Phe2) and 
an aliphatic amino acid in the C-terminus [8]. All studies 
carried out so far have demonstrated the importance of 
Ty? for efficient binding to H-2Kd [5,9-111. However, allele- 
specific motifs are necessary for binding but not sufficient by 
themselves [12]. Several studies were performed to determine 
the influence at non-anchor positions of positive and negative 
interactions. These studies consisting of binding motif refine- 
ment used individual peptides in competitive assays. Results 
indicated that some residues have a harmful effect on binding. 
In this way especially Pro or acidic residues should be avoided 
at position 3 as well as Phe or charged residues at position 5 
in the sequences of particular Kd ligands [13,14]. 
Therefore, to confirm these observations and extend the 
refinement at other positions, we recently used synthetic pep- 
tide libraries in binding assays with the Kd molecule [15]. In a 
parent Kd binding sequence, SYIPSAEYI named 2Y in this 
study, an analog of the 252-260 antigenic peptide derived 
from the Plasmodium berghei circumsporozoite protein, each 
position was replaced by all natural amino acids (except Cys). 
Each library obtained for the substitution of one position in 
the parent sequence was then tested for selection by the Kd 
molecule. Our work showed that when the library binding 
tests were carried out in noncompetitive conditions a much 
broader set of peptides binds to H-2Kd than expected from 
previous studies. The pattern of accepted residues varied at 
each position. Positions 2, 3 and 9 were quite restrictive while 
others were more permissive. In addition to the selection of 
Tyr and Phe at position 2, the selection of three other resi- 
dues, i.e. Leu, Ile and Met, was the most surprising result of 
this study. 
Here we report that the new H-2Kd ligands identified in our 
former study, which do not fit the consensus motif because 
Tyr’ was substituted by Leu, Ile or Met, are intermediate- 
affinity peptides. The affinity of the new ligands was compared 
with the affinity of the parent peptide. This peptide was pre- 
viously shown to be Kd restricted [12]. The binding assays 
were performed with a single-chain, soluble H-2Kd molecule 
(SC-Kd) [16]. The C-terminal end of the cc3 domain of this 
molecule is connected to the N-terminal end of mouse pz- 
microglobulin. This fusion protein had been previously shown 
to be functionally empty, to bind the same repertoire as the 
native cell-surface expressed H-2Kd molecule [12] and to spe- 
cifically stimulate Kd-restricted T cells [17]. The relative affi- 
nities of the new ligands were evaluated by competitive bind- 
ing of radiolabeled control Kd-restricted peptide to purified 
SC-Kd. The binding affinities were slightly affected by the 
substitution of Tyr2 by Leu, Ile or Met and the new ligands 
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correspond to intermediate binders according to the classifica- 
tion of Grey et al. [18]. The best competitor was tested for its 
ability to induce CTLs in vivo as well as positive and negative 
controls and a peptide with a very weak binding affinity. The 
identification of such intermediate- or even low-affinity pep- 
tides capable of eliciting CTL response may be useful for 
developing new therapeutic approaches. 
2. Materials and methods 
2.1. Peptides and peptide synthesis 
Peptides (Table 1) were prepared by automated solid-phase syn- 
thesis using Fmoc chemistry and Wang resins on an Applied Biosys- 
terns Peotide Svnthesizer (Model 431A. Foster Citv. CA, USA). Side- 
1 d I_ , 
chain protecting group was OtBu for Glu, Ser and Tyr. Fmoc amino 
acids were coupled after activation with dicyclohexylcarbodiimide/l- 
hydroxybenzotriazole. Fmoc deprotection of the peptidyl-resin before 
each coupling was performed with 20% piperidine in N-methylpyrro- 
lidone. Side-chain deprotection and cleavage from the solid support 
were achieved in trifluoroacetic acid with phenol as a scavenger [19]. 
Peptides were precipitated in diethyl ether. They were purified by 
reversed-phase HPLC (RP-HPLC). Their purity was then assessed 
by analytical RP-HPLC and MALDI mass spectrometric analysis. 
2.2. Peptide binding assays 
The soluble single chain Kd, SC-Kd, molecule was expressed in 
transfected CHO cells as previously described [20]. SC-Kd was puri- 
fied from the culture medium by affinity chromatography using the 
Kd-specific SFl- 1.1.1 monoclonal antibody (mAb). 
The relative affinities of peptides were determined in a competition 
binding assay. The Kd-restricted control peptide, 2Y, was labeled 
using chloramine T-catalyzed iodination to a specific activity of about 
60 Ci/mmol [21]. Free iodine was removed by ion exchange chroma- 
tography on an AGl lA8 column (BioRad, France). 10 ng (9.6 pmol) 
of labeled peptide 2Y’ was incubated in PBS with 100 ng (2 pmol) of 
SC-Kd in the presence of increased concentration of the test peptide 
for 1.5 h at room temperature. Peptide-MHC complexes were immu- 
noprecipitated using SF 1 - 1.1.1 mAb. Radioactivity in the precipitated 
pellet was measured in a y-counter (Gammamatic, Kontron). Reduc- 
tion of the radioactivity in the pellet indicates competitive binding of 
the test peptides. The binding capacity of each competitor is deter- 
mined according to the ICas and the relative affinity. I& is the con- 
centration of the competitor peptide that inhibits the radiolabeled 
control peptide binding by 50%. The relative affinity of each compe- 
titor was calculated as previously described [22]. Briefly, 
K,,, = It&/( 1 + [2Y*]/KA) where [2Y’] = 0.4 pM and K; is the affi- 
nity of radiolabeled control peptide (30 nM) [12]. 
2.3. Mice 
6-g-week old BALBlc (H-2d) female mice were obtained from the 
National Institute of Medical Research (Mill Hill, London, UK). 
2.4. Cells 
Target cells used in cytotoxicity assays were P815 (H-2d, MHC class 
I+ and MHC class II-) mastocytoma cells and were grown in RPM1 
1640 medium supplemented with 10% fetal calf serum. Peptide-pulsed 
P815 cells were prepared for use as targets by prior incubation with a 
100 pl volume of the appropriate concentration of peptide. 
2.5. Immunizations 
BALB/c mice were injected subcutaneously (s.c.) with 100 nmol of 
2Y and 2L dissolved in PBS and emulsified in incomplete Freund’s 
adjuvant (IFA) (1: 1). After 14 days, mice were killed and spleen cells 
were removed for in vitro lymphocyte restimulation with designated 
peptides for 7 days, in 10% concanavalin A supernatant containing 
medium, which acts as a source of interleukin-2. 
2.6. CTL assay 
P815 (H-2d) target cells were labeled with 51Cr by incubation with 
200 pCi Nas1Cr04 (NEN Research Products, Boston, MA) for 1 h. 
After washing, lo6 P815 cells were pulsed with each peptide (50 nmol 
in 100 pl HBSS) at 37°C for 1 h. The unbound peptide was removed 
by three washes with HBSS (Gibco Laboratories, Uxbridge, UK). 
Graded numbers of effector cells were mixed with lo4 peptide pulsed 
labeled target cells in RPM1 1640 medium containing 10% FCS in the 
wells of round-bottom microtiter plates, followed by incubation at 
37°C for 6 h. Supernatant (100 pl) was taken from each well and 
the radioactivity detected in a y-counter. The percentage of specific 
lysis was determined using the formula: [(cpm released by CTL-cpm 
released with medium alone)/(cpm released by detergent-cpm re- 
leased with medium alone)] X 100. The detergent used to determine 
maximum release was 5% Triton X-100. Spontaneous release was 
determined from target cells incubated without the addition of effector 
cells. The assay was performed in triplicate. 
3. Results 
3.1. Peptide binding to SC-I@ 
Different analogs of the Kd-restricted 2Y peptide were 
synthesized (Table 1) and their binding capacity to Kd was 
assessed by competition binding assay with SC-Kd. Competi- 
tive binding activities of 2L and 9A are represented in Fig. 1. 
With increasing concentration of 2L, the binding of 1251-la- 
beled control peptide SYIPSAEYI was significantly reduced. 
In the case of 9A, the bound radioactivity was displaced only 
when a large concentration of competitor was used. When a 
7.5 molar excess of competitor was used (i.e. 3 uM of com- 
petitor), the binding capacity of 2L, 2M and 21 was slightly 
lower than that of the unlabeled control peptide (Fig. 2). 
However, they were high enough to displace more than 50% 
of the bound radioactivity while the other peptides 2A, 9A 
and 2A9A, under the same conditions, showed no significant 
binding. When a large excess of competitor was used (i.e. 150 
molar excess that is equivalent to a competitor concentration 
of 60 PM), 2A and 9A were able to bind while 2A9A had still 
no competitive binding activity. IC5a values ranged from 1 to 
2 uM for 2L, 2M and 21. 2L bound to SC-Kd most efficiently 
with an ICsa of 1 uM (relative affinity -70 nM). 2A and 9A 
bound less efficiently with I& values over 20 uM and were 
weak binders for SC-Kd. 
3.2. Induction of CTL 
The immunogenic activities of a strong, an intermediate, a 
weak and a non-binder to SC-Kd (i.e. respectively 2Y, 2L, 9A 
and 2A9A) were assessed using CTL from BALB/c mice im- 
munized with 100 pg of the designated peptide emulsified in 
IFA. CTL activity was tested in a 51Cr release assay against 
peptide loaded P815 cells. 
Lymphocytes from mice immunized with 2Y expressed high 
level CTL activity while lymphocytes from mice immunized 
with 2L and 9A showed moderate to weak cytolytic activity 
(Fig. 3). Target cells without peptide and cells loaded with the 
Table 1 
Peptide sequences used in this work and their binding affinity for 
SC-Kd 
Code Residue position Ko(nM) 
1 2 3 4 5 6 7 8 9 
2Y S Y I P s A E Y I 30a 
2L _ L _ ~ ~ _ _ _ _ 70b 
21 _ I _ _ ~ _ _ _ _ 140b 
2M _ M_ _ ~ ~ ~ _ _ 77b 
2A _ A------~ 2094b 
9A _ L ~ _ _ _ _ _ A 1396b 
2A9A - A - ~ - - - - A n.d. 
aK~ was determined previously by Scatchard analysis [12]. 
bRelative binding affinity was evaluated as described in section 2. 
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non-binder 2A9A peptide were lysed to a very weak extent 
(Fig. 3). 
4. Discussion 
Many studies have already shown that peptides, in spite of 
bearing the allele-restricted motif, did not bind to the consid- 
ered allele. For example, several peptides found in the se- 
quence of antigenic proteins, which displayed the reported 
Kd-restricted motif, had no affinity for Kd [13,23]. Therefore, 
the screening for MHC binding peptides in the sequence of 
antigenic proteins merely based on the detection of anchor 
residues cannot ensure that peptides thus selected, then re- 
synthesized by chemical methods, and tested for their capacity 
to induce a CTL response could prove efficient binders. Sev- 
eral additional refinements must be carried out and particu- 
larly positive and negative interactions at non-anchor posi- 
tions must be elucidated in order to allow good prediction 
of binding peptides. 
In the work reported here, we confirm that some peptides 
devoid of the Tyr2 anchor residue are nevertheless able to 
bind to Kd. The peptides 2L, 2M and 21 were first identified 
in a previous study in which interaction tests with the Kd 
molecule were carried out with peptide libraries under non- 
competitive conditions [15]. These peptides have a reasonable 
binding capacity to Kd and can be considered as intermediate 
binders according to the classification of Grey et al. [18]. In 
order to confirm the role of Let?, Met2 and Ile’ in binding, 
the affinities of the three peptides containing these residues 
were compared with the affinities of peptides in which one 
of the two anchor positions or both were substituted by 
Ala. Disubstituted 2A9A peptide was unable to bind to Kd, 
indicating that, in this sequence, there is no other effective 
anchoring position than 2 and 9. Monosubstituted peptides 
2A and 9A both bind significantly to Kd but could compete 
with the labeled control peptide only when added in large 
amounts (Fig. 2). Thus, the presence of a single anchor resi- 
due confers to the ligand a pattern of weak binder. Now 
comparing the affinities of 2Y, 2L, 2M and 21 with the 
weak ligand 2A, it appears that the presence of Tyr, Leu, 
120 
O,l 1 10 100 
PEPTIDE CONCENTRATION (PM) 
Fig. 1. Labeled control peptide binding to Kd. Different concentra- 
tions of test peptides (Table 1) were used to displace the labeled 
peptide. 2L (0) and 9A (X) test peptides were compared to unla- 
beled positive control Kd-restricted peptide 2Y (m) and to negative 
control 2A9A peptide (A), which does not contain Kd-anchor resi- 














Fig. 2. Control peptide binding inhibition. Peptide binding to Kd 
was assayed in the competition test described in Section 2. SC-Kd 
(100 ng) was incubated with 0.4 pM 1251-labeled Kd-restricted pep- 
tide in the presence of 3 uM (closed bar) or 60 uM (hatched bar) 
of unlabeled test peptide. Results are expressed as percent inhibition 
of labeled peptide binding. 
Met or Ile in position 2 enhances greatly the binding to nearly 
the same order of magnitude. These results confirm that posi- 
tion 2 is an integral part of the Kd motif. Leu, Ile or Met at 
this position are efficient substitutes of the Tyr2 anchor resi- 
due. The affinity of the best competitor (i.e. 2L) identified in 
this study is only 2.5 times weaker than this of the control 
peptide. It seems surprising therefore that the three amino 
acids identified in position 2 in our previous work had never 
been described by the method in which naturally occurring 
peptides are eluted from Kd and sequenced [4]. Several rea- 
sons could be put forward: (i) no or a few peptides with Leu, 
Met or Ile in position 2 are processed in the cytosol by the 
proteasome; (ii) processed peptides with L2, M2 or I2 cannot 
bind to TAP transporters and therefore cannot reach the ER 
where the association with the Kd molecule takes place; (iii) 
as our binding test was performed with synthetic libraries, the 
composition of the libraries did not necessarily resemble the 
natural peptide mixture existing in the ER so that our syn- 
thetic libraries could contain some peptides not naturally pro- 
cessed and presented. 
We show in the present study that several new Kd ligands 
could induce a cytotoxic response. The efficacy of CTL induc- 
tion seems to parallel closely the binding capacity to Kd as the 
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Fig. 3. Induction of CTL with SC-Kd binding peptides. BALB/c 
mice were injected S.C. in the tail base with 100 pg of 2Y (square), 
2L (triangle), 9A (lozenge) or 2A9A (circle) emulsified in IFA. 
Spleen cells were removed 14 days after injection and were restimu- 
lated in vitro with designated peptides for 7 days. CTL activity was 
measured by the lysis of target cells with (closed symbols) or with- 
out (open symbols) specific peptide. 
cytolytic activity of the strongest binder 2Y was higher than 
all others. Lymphocytes from mice immunized with 2L, 9A 
and 2A9A showed decreasing cytolytic activity in proportion 
with their decreasing binding affinities. Peptide affinity for the 
MHC was reported to be a factor contributing to the number 
of specific complexes expressed on the antigen presenting cell 
surface [20]. Peptides with high affinity induce a strong expres- 
sion of peptide-MHC complexes. On the other hand, low-af- 
finity interactions do not generate enough complexes or com- 
plexes sufficiently stable to trigger a response. However, in our 
work, the cytolytic activity against the weak-binder 9A was 
not non-existent. Therefore, by enhancing its immunogenicity 
either by encapsulation in liposomes or by covalent associa- 
tion with lipids or by co-immunization with a T-helper epi- 
tope as recently reported [24], it would certainly be possible to 
obtain a high cytolytic activity against it. 
In the work reported here, we show that many more pep- 
tides than these described by Rammensee et al. bind to Kd [S]. 
In addition to the results of Rammensee et al., ours will be 
useful for the identification of many more T epitopes in viral 
or tumoral protein sequences. However, to induce a cytolytic 
activity in vivo, it remains to be determined whether the inter- 
mediate- and low-affinity peptides identified in this work are 
naturally processed and presented. If this is the case, they 
seem to be presented by Kd at concentrations too low to 
succeed in being identified by the extraction and sequencing 
method. However, as only a few complexes are necessary for 
cytolysis, these peptides may become the in vivo target of 
highly reactive and specific CTLs pulsed with these peptides 
ex vivo [25]. 
The recognition of peptides by class I-restricted CTLs offers 
the unique opportunity to develop immunotherapeutics for 
treating or preventing viral infections and tumour growth. 
Therefore, methods leading to the identification of class I 
binding peptides and putative T cell epitopes are of particular 
interest. Our method using synthetic peptide libraries with 
known compositions and non-competitive binding tests with 
the class I molecule seems the technique of choice for this 
purpose. It should now be exploited for the identification of 
new ligands of other class I molecules. 
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